GlobalData’s patient-based forecast predicts Tecvayli will reach a peak of $2.1bn in sales globally by 2030 in MM.
Innovations in rare blood disorders took center stage at the 2024 American Society of Hematology (ASH) Annual Meeting & ...
Johnson & Johnson announced new frontline data featuring TECVAYLI from two investigational studies in patients with newly diagnosed ...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patientsNew analysis from the IMROZ phase 3 ...
The following is a summary of “Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®â–¼ (teclistamab) from two investigational studies in patients with newly diagnosed ...
New data from three oral presentations, which demonstrated significant clinical benefit with Sarclisa-based quadruplets in newly diagnosed multiple myeloma (NDMM) patients were featured at the 66th ...
ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients New analysis from the IMROZ phase 3 study of Sarclisa-VRd demonstrated higher and sustained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback